Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…
Browsing: Breast
Breast Cancer
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated…
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated…
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated…
Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic…
Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic…
Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic…
Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer…
Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer…
Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer…
Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose…
Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose…
Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural…
Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural…
Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization…
Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization…
Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization…
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the importance of real…
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes…
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses the impact of multigenomic assays in premenopausal patients and those with…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine explains how important it is to tailor treatment for triple-negative breast cancer patients.…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine answers how come interferon gamma is acting differently? _____________ Immunotherapies have revolutionized care…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine discusses tailoring revolutionary treatment for triple-negative breast cancer. _____________ Immunotherapies have revolutionized care…
Earn CME: https://www.naccme.com/program/19-cpc-101-1 This webcast features a presentation by Dr. Nicole M. Kuderer that examines pharmacological profiles of novel and…
Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses the effects of cardiac toxicities in the phase 3 CLEOPATRA study…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer answers common questions in the phase 3 CLEOPATRA study in HER2 metastatic…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast…
While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation…
Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich answers commonly asked questions in pharmacogenomics and endocrine therapy in breast…
– Application Supported by Results of Pivotal HER2CLIMB Trial -Â – First Investigational Therapy in a Pivotal Trial to Include…
Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich discusses endocrine therapy in breast cancer.
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer explains getting results down in oral paclitaxel: a Phase III clinical…
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer answers frequently asked questions on paclitaxel shown to be superior to…
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer on paclitaxel shown to be superior to IV paclitaxel on confirmed…
First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic…